Analgesia and physiotherapy in children with cerebral palsy (ANTALKINECP)
- Conditions
- Cerebral PalsyMedDRA version: 18.1 Level: PT Classification code 10008129 Term: Cerebral palsy System Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Not possible to specify
- Registration Number
- EUCTR2015-005538-23-FR
- Lead Sponsor
- CHRU de Brest
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Not specified
- Target Recruitment
- 180
• Cerebral palsy hemiplegic diplegic or tetraplegic spastic or not.
• Children who feel pain during the pre-screening physiotherapy session with a VAS score above 2 (or 1 on the FPS).
• Aged 6 to 17 years of both gender.
• Ability to express his/her pain and to measure its intensity with VAS or FPS.
• Informed and signed (parents, investigator and child if possible).
Are the trial subjects under 18? yes
Number of subjects for this age range: 180
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
• Lack of physiotherapy or frequency below every fortnight.
• Analgesic treatment already available or stopped in the last month.
• Severe infection or instable vital functions.
• Child unable to cooperate.
• Hypersensitivity to ibuprofen or any of the constituents in the product.
• History of allergy or asthma triggered by taking ibuprofen or substances of near activity such as other NSAIDs and aspirin.
• Allergy to other component of the capsule.
• Allergy or intolerance to lactose
• History of upper gastrointestinal bleeding or perforation, related to previous NSAID therapy.
• Active gastrointestinal ulcer.
• Severe hepatic failure.
• Severe renal failure.
• Uncontrolled severe cardiac failure.
• Systemic Lupus Erythematosus.
• Scheduled surgery procedure during or between the period of the assessment of pain
• Regular intake of ibuprofen
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method